Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: Implications for basal-like breast cancer

Oncogene

Volumn 32, Issue 11, 2013, Pages 1428-1440

  Gastaldi, S ^a,b,f   Sassi, F ^a,b   Accornero, P ^c   Torti, D ^a,b   Galimi, F ^a   Migliardi, G ^a,b   Molyneux, G ^d   Perera, T ^e   Comoglio, P M ^a,b   Boccaccio, C ^a,b   Smalley, M J ^d,g   Bertotti, A ^a,b   Trusolino, L ^a,b  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g European Cancer Stem Cell Research Institute   (United Kingdom)

Author keywords

basal like breast cancer; cell fate determination; mammary morphogenesis; mammary stem cells; mammary tumorigenesis; Met tyrosine kinase receptor

Indexed keywords

ANTINEOPLASTIC AGENT; GEFITINIB; JNJ 38877605; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL CELL; BREAST CARCINOMA; BREAST EPITHELIUM; BREAST HYPERPLASIA; CELL DIFFERENTIATION; CELL EXPANSION; CELL FATE; CELL GROWTH; CELL LINEAGE; CELL MATURATION; CELL PROLIFERATION; CELL SPECIFICITY; CELL SUBPOPULATION; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LUMINAL PROGENITOR CELL; MAMMARY GLAND; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CELLS, CULTURED; EPITHELIAL CELLS; FEMALE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASMS, BASAL CELL; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 84875215810     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.154     Document Type: Article

References (60)

1. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML et al. Generation of a functional mammary gland from a single stem cell. Nature 2006; 439: 84-88. (Pubitemid 43053633)
2. Sleeman KE, Kendrick H, Ashworth A, Isacke CM, Smalley MJ. CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res 2006; 8: R7.
3. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D et al. Purification and unique properties of mammary epithelial stem cells. Nature 2006; 439: 993-997. (Pubitemid 43292419)
4. Taddei I, Deugnier MA, Faraldo MM, Petit V, Bouvard D, Medina D et al. Beta1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. Nat Cell Biol 2008; 10: 716-722. (Pubitemid 351772937)
5. Sleeman KE, Kendrick H, Robertson D, Isacke CM, Ashworth A, Smalley MJ. Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol 2007; 176: 19-26. (Pubitemid 46041676)
6. Asselin-Labat ML, Sutherland D, Barker H, Thomas R, Shackleton M, Forrest NC et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 2007; 9: 201-209. (Pubitemid 46420863)
7. Eirew P, Stingl J, Raouf A, Turashvili G, Aparicio S, Emerman JT et al. A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat Med 2008; 14: 1384-1389.
8. Stingl J, Eaves CJ, Zandieh I, Emerman JT. Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue. Breast Cancer Res Treat 2001; 67: 93-109. (Pubitemid 32744490)
9. Villadsen R, Fridriksdottir AJ, Rønnov-Jessen L, Gudjonsson T, Rank F, LaBarge MA et al. Evidence for a stem cell hierarchy in the adult human breast. J Cell Biol 2007; 177: 87-101. (Pubitemid 46588404)
10. Van Keymeulen A, Rocha AS, Ousset M, Beck B, Bouvencourt G, Rock J et al. Distinct stem cells contribute to mammary gland development and maintenance. Nature 2011; 479: 189-193.
11. Visvader JE. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev 2009; 23: 2563-2277.
12. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
13. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423. (Pubitemid 36842560)
14. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7: 96.
15. Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 2007; 7: 791-799. (Pubitemid 47463670)
16. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-1948.
17. Chaffer CL, Weinberg RA. Cancer cell of origin: Spotlight on luminal progenitors. Cell Stem Cell 2010; 7: 271-272.
18. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4: 814-819. (Pubitemid 39331153)
19. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009; 15: 907-913.
20. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010; 7: 403-417.
21. Mackay A, Weigelt B, Grigoriadis A, Kreike B, Natrajan R, A'Hern R et al. Microarraybased class discovery for molecular classification of breast cancer: Analysis of interobserver agreement. J Natl Cancer Inst 2011; 103: 662-673.
22. Boccaccio C, Comoglio PM. Invasive growth: A MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006; 6: 637-645. (Pubitemid 44140861)
23. Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci USA 2009; 106: 12909-12914.
24. Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci USA 2009; 106: 12903-12908.
25. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834-848.
26. Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol 2007; 38: 830-841. (Pubitemid 46726507)
27. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-925.
28. Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E et al. Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci Signal 2009; 2: Ra80.
29. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009; 15: 2207-2214.
30. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: Targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7: 504-516. (Pubitemid 351767118)
31. Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, Perera T et al. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res 2010; 70: 7580-7590.
32. Galimi F, Torti D, Sassi F, Isella C, Cora D, Gastaldi S et al. Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: Response to met inhibition in patient xenografts and pathologic correlations. Clin Cancer Res 2011; 17: 3146-3156.
33. Torti D, Sassi F, Galimi F, Gastaldi S, Perera T, Comoglio PM et al. A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. Int J Cancer 2012; 130: 1357-1366.
34. Bublil EM, Yarden Y. The EGF receptor family: Spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 2007; 19: 124-134. (Pubitemid 46386405)
35. Niranjan B, Buluwela L, Yant J, Perusinghe N, Atherton A, Phippard D et al. HGF/SF: A potent cytokine for mammary growth, morphogenesis and development. Development 1995; 121: 2897-2908.
36. Yang Y, Spitzer E, Meyer D, Sachs M, Niemann C, Hartmann G et al. Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland. J Cell Biol 1995; 131: 215-226.
37. Sebastian J, Richards RG, Walker MP, Wiesen JF, Werb Z, Derynck R et al. Activation and function of the epidermal growth factor receptor and erbB-2 during mammary gland morphogenesis. Cell Growth Differ 1998; 9: 777-785. (Pubitemid 28425874)
38. Wiesen JF, Young P, Werb Z, Cunha GR. Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. Development 1999; 126: 335-344. (Pubitemid 29083971)
39. Schroeder JA, Lee DC. Transgenic mice reveal roles for TGFalpha and EGF receptor in mammary gland development and neoplasia. J Mammary Gland Biol Neoplasia 1997; 2: 119-129. (Pubitemid 127716441)
40. Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A et al. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 1999; 126: 2739-2750. (Pubitemid 29338634)
41. Sternlicht MD, Sunnarborg SW, Kouros-Mehr H, Yu Y, Lee DC, Werb Z. Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development 2005; 132: 3923-3933. (Pubitemid 41410256)
42. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant nonsmall-cell lung cancer. Nat Rev Cancer 2010; 10: 760-774.
43. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011; 364: 947-955.
44. Bozec A, Formento P, Lassalle S, Lippens C, Hofman P, Milano G. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: Antitumour supraadditive effects on human head and neck cancer xenografts. Br J Cancer 2007; 97: 65-72. (Pubitemid 47012080)
45. Shimoyama T, Koizumi F, Fukumoto H, Kiura K, Tanimoto M, Saijo N et al. Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR. Lung Cancer 2006; 53: 13-21. (Pubitemid 43831356)
46. Kendrick H, Regan JL, Magnay FA, Grigoriadis A, Mitsopoulos C, Zvelebil M et al. Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC Genomics 2008; 9: 591.
47. Birchmeier C, Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 1998; 8: 404-410. (Pubitemid 28458706)
48. Rosário M, Birchmeier W. How to make tubes: Signaling by the Met receptor tyrosine kinase. Trends Cell Biol 2003; 13: 328-335. (Pubitemid 36638800)
49. Gjorevski N, Nelson CM. Integrated morphodynamic signalling of the mammary gland. Nat Rev Mol Cell Biol 2012; 12: 581-593.
50. Jackson-Fisher AJ, Bellinger G, Ramabhadran R, Morris JK, Lee KF, Stern DF. ErbB2 is required for ductal morphogenesis of the mammary gland. Proc Natl Acad Sci USA 2004; 101: 17138-17143. (Pubitemid 39627787)
51. Andrechek ER, White D, Muller WJ. Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth. Oncogene 2005; 24: 932-937. (Pubitemid 40216100)
52. Jones FE, Jerry DJ, Guarino BC, Andrews GC, Stern DF. Heregulin induces in vivo proliferation and differentiation of mammary epithelium into secretory lobuloalveoli. Cell Growth Differ 1996; 7: 1031-1038. (Pubitemid 26360714)
53. Jones FE, Welte T, Fu XY, Stern DF. ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation J Cell Biol 1999; 147: 77-88.
54. Brisken C, Heineman A, Chavarria T, Elenbaas B, Tan J, Dey SK et al. Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev 2000; 14: 650-654. (Pubitemid 30176819)
55. Simian M, Hirai Y, Navre M, Werb Z, Lochter A, Bissell MJ. The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells. Development 2001; 128: 3117-3131. (Pubitemid 32825756)
56. Finkbeiner MR, Astanehe A, To K, Fotovati A, Davies AH, Zhao Y et al. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene 2009; 28: 1421-1431.
57. Gastaldi S, Comoglio PM, Trusolino L. The Met oncogene and basal-like breast cancer: Another culprit to watch out for? Breast Cancer Res 2010; 12: 208.
58. Ponzo MG, Park M. The Met receptor tyrosine kinase and basal breast cancer. Cell Cycle 2010; 9: 1043-1050.
59. Regan JL, Kendrick H, Magnay FA, Vafaizadeh V, Groner B, Smalley MJ. c-Kit is required for growth and survival of the cells of origin of Brca1-mutationassociated breast cancer. Oncogene 2012; 31: 869-883.
60. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004; 6: 61-73. (Pubitemid 38903162)